Project 1: Analysis of 2nd phase decay in persons living with HIV

项目 1:艾滋病毒感染者第二阶段衰退分析

基本信息

  • 批准号:
    10459661
  • 负责人:
  • 金额:
    $ 40.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2027-03-31
  • 项目状态:
    未结题

项目摘要

Summary – Project 1 The development of an accurate assay for plasma HIV-1 RNA provided important insights into HIV-1 pathogenesis and accelerated the development of effective treatments. Co-investigator Alan Perelson used frequent plasma HIV-1 RNA measurements to demonstrate a biphasic decay in viremia following the initiation of combination antiretroviral therapy (ART). Following a very rapid initial decay in the first days few days of treatment, viremia falls more slowly over the new few weeks. The half-lives of these two phases of decay of viremia (termed here 1st and 2nd phase) are 1 day and 14 days, respectively. Fundamental principles of viral dynamics2-4 developed by Dr. Perelson suggest that the biphasic decay must reflect the presence of two distinct populations of virus producing cells with corresponding decay rates 1 day and 14 days. However, this prediction has yet to be verified. Concomitant measurement of changes in infected cell frequencies following ART initiation has been complicated by several factors including the presence of large numbers of defective proviruses. The recent development of digital droplet PCR assays for intact proviruses has allowed us to make such measurements in persons living with HIV-1 (PLWH) who are initiating ART and in SIV-infected macaques. In this proposal, we focus on the 2nd phase of decay of viremia which continues for several weeks after the very rapid 1st phase decay has eliminated most productively infected cells. Our fundamental hypothesis is that the 2nd phase decay represents a selection process which determines which cells will enter the stable latent reservoir. Only cells that survive this phase of decay may be able to downregulate HIV-1 gene expression and enter the stable latent reservoir, which we have shown has half-life measured in years (3.7 years). Therefore, we will analyze 2nd phase decay to develop novel insights into the composition and dynamics of the latent reservoir that may suggest new strategies for curing HIV-1 infection.
摘要-项目1 血浆HIV-1RNA准确检测的发展为了解HIV-1提供了重要的见解 发病机制及加速发展的有效治疗方法。联合调查员艾伦·佩雷尔森用 频繁的血浆HIV-1RNA检测显示病毒血症开始后出现双相衰变 联合抗逆转录病毒疗法(ART)。在经历了最初几天非常迅速的腐烂之后 治疗后,病毒血症在新的几周里下降得更慢。这两个衰变阶段的半衰期 病毒血症(这里称为1期和2期)分别为1天和14天。病毒的基本原理 Perelson博士发展的动力学2-4表明,两相衰变必须反映出两种截然不同的 病毒产生细胞的数量,相应的衰减率分别为1天和14天。然而,这一预测 尚未得到证实。抗逆转录病毒治疗开始后感染细胞频率变化的伴随测量 有几个因素使情况变得复杂,包括存在大量有缺陷的前置文件。这个 最近对完整前病毒的数字液滴聚合酶链式反应分析的发展使我们能够做出这样的 对开始抗逆转录病毒治疗的HIV-1携带者(PLWH)和感染SIV的猕猴进行测量。在……里面 这项建议,我们把重点放在病毒血症的第二个衰变阶段,这个阶段在非常 快速的第一阶段腐烂已经消除了最具生产力的感染细胞。我们的基本假设是 第二相衰变是一种选择过程,它决定了哪些细胞将进入稳定潜伏期 水库。只有在这一腐烂阶段存活下来的细胞才能下调HIV-1基因的表达,并 进入稳定的潜在储集层,我们已经证明了它的半衰期是以年(3.7年)为单位的。因此, 我们将分析第二相衰变,以发展对潜伏期的组成和动力学的新见解。 这可能会为治愈HIV-1感染提出新的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT F SILICIANO其他文献

ROBERT F SILICIANO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT F SILICIANO', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10599358
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10459659
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
Project 1: Analysis of 2nd phase decay in persons living with HIV
项目 1:艾滋病毒感染者第二阶段衰退分析
  • 批准号:
    10599360
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
Understanding reservoir dynamics through analysis of viral decay processes
通过分析病毒衰变过程了解储存库动态
  • 批准号:
    10599356
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
Understanding reservoir dynamics through analysis of viral decay processes
通过分析病毒衰变过程了解储存库动态
  • 批准号:
    10459658
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
Host and viral genomic determinants of HIV latent reservoir size and characteristics in individuals with substance use disorders
艾滋病毒潜伏库大小和物质使用障碍个体特征的宿主和病毒基因组决定因素
  • 批准号:
    10661843
  • 财政年份:
    2018
  • 资助金额:
    $ 40.12万
  • 项目类别:
Host and viral genomic determinants of HIV latent reservoir size and characteristics in individuals with substance use disorders
艾滋病毒潜伏库大小和物质使用障碍个体特征的宿主和病毒基因组决定因素
  • 批准号:
    9764318
  • 财政年份:
    2018
  • 资助金额:
    $ 40.12万
  • 项目类别:
Host and viral genomic determinants of HIV latent reservoir size and characteristics in individuals with substance use disorders
艾滋病毒潜伏库大小和物质使用障碍个体特征的宿主和病毒基因组决定因素
  • 批准号:
    10619974
  • 财政年份:
    2018
  • 资助金额:
    $ 40.12万
  • 项目类别:
Project 2 - Identification of the source of viral rebound using SIV proviral genome analysis
项目 2 - 使用 SIV 原病毒基因组分析识别病毒反弹的来源
  • 批准号:
    9322142
  • 财政年份:
    2017
  • 资助金额:
    $ 40.12万
  • 项目类别:
Developmental
发育性
  • 批准号:
    8292622
  • 财政年份:
    2012
  • 资助金额:
    $ 40.12万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 40.12万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 40.12万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 40.12万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 40.12万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 40.12万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了